Month: March 2023

Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression Nomination of multiple development candidates anticipated in 2023 Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided corporate updates. “Last year...

Strong order book growth; initial deliveries slated to begin in 4Q23Achieved key development milestones in 2022 on time and in line with budget with total operating expenses of $127 million Liquidity of $154 million supports anticipated non-GAAP operating expense of $70-$75 million for 2023 with P7 program fully funded into commercialization Strong order book growth for Powered by REE vehicles growing customer base from 2 to 8 since reporting 3Q22 results with 35 firm orders as of today Delivered 2 prototypes to an OEM for customer evaluation and testing Grew our go to market strategy by achieving direct sales and entering into additional dealership agreements in the US Provided suppliers with 2023-24 production forecast; built the first batch of production intent P7 vehicles for validation; certification activities underway Company...

Maroussi, Greece, March 16, 2023 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (the “Company” or “Pyxis Tankers”), an international pure-play product tanker company, today announced unaudited results for the three months and year ended December 31, 2022. Summary For the three months ended December 31, 2022, our Revenues, net were $18.4 million. For the same period, our time charter equivalent (“TCE”) revenues were $13.8 million, an increase of approximately $10.0 million or 256% from the comparable quarter in 2021. Our net income attributable to common shareholders for the three months ended December 31, 2022 was $6.5 million, representing an increase of $12.1 million from a net loss of $5.6 million in the comparable period in 2021. For the fourth quarter of 2022, the net income per share was $0.61 basic and $0.53 diluted compared to a...

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate UpdateClinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-beta vaccine for Alzheimer’s disease (AD) showed positive initial safety and immunogenicity in Phase 1b/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024 ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment 2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million providing runway into...

MIDDLETOWN, R.I., March 16, 2023 (GLOBE NEWSWIRE) — KVH Industries, Inc., (Nasdaq: KVHI), reported financial results for the quarter and full year ended December 31, 2022 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company’s website. Fourth Quarter 2022 HighlightsTotal revenues from continuing operations increased by 2% in the fourth quarter of 2022 to $36.0 million from $35.3 million in the fourth quarter of 2021.Our VSAT Broadband airtime revenue increased 12% year-over-year to $26.8 million, despite the shutdown of our legacy network on December 31, 2021.Net income from continuing operations in the fourth quarter of 2022 was $0.6 million, or $0.03 per...

– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical data by the first half of 2024 – PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “As we seek FDA clearance for CABA-201 in the next few months, we believe that our specifically designed product candidate for autoimmune patients, our experience with efficient autoimmune cell therapy clinical trial design coupled with...

Continued consumer purchases (scanned retail sales) growth of 24% for the 52 weeks ended January 28, 20231Q1 2023 net revenue decreased to $5.0 million, compared to $7.0 million in Q1 2022, mainly due to the remaining balance of an initial pipeline fill in Q1 2022 and a reduction in inventory on hand by the exclusive Canadian distributor in Q1 2023 Sustained strong gross margin of 53.7% in Q1 2023, compared to 54.5% in Q1 2022 Adjusted EBITDA2 loss of $2.6 million in Q1 2023, versus a $3.0 million loss in Q1 2022 Strong financial position with over $52.5 million in cash and cash equivalents, short-term investments and unused credit facilities, reflecting prudent balance sheet management Subsequent to Q1, appointment of Rajaa Grar as Chief Revenue Officer, an award-winning brand marketing and digital global leader, to drive GURU’s...

Reports Fourth Quarter 2022 Loss Lower than Prior GuidanceExpects Double-Digit Operating Margins in Back Half of 2023Expects a Return to Profitability for Full Year 2023 SECAUCUS, N.J., March 16, 2023 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty apparel retailer in North America, today announced financial results for the fourth quarter and fiscal year ended January 28, 2023. Jane Elfers, President and Chief Executive Officer commented, “As we previously announced, our 2022 operating results were negatively impacted by unprecedented input costs – the spike in cotton prices, airfreight, and container costs. While we still need to work through this higher cost inventory during the front half of 2023, input cost reductions in the back half of 2023, combined with our strong...

–-Registration Trial for uUTI Ongoing and On Track-––-Cash Runway until Mid-2024– –Company to host conference call today at 8:30amET– DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2022. “We made significant progress in 2022 to move the clinical development of oral sulopenem forward leading to a potential resubmission of our new drug application (“NDA”) next year,” said Corey Fishman, Iterum’s Chief Executive Officer. “Enrollment in our REASSURE trial, which...

– 19% Full Year Adjusted EBITDA Growth – – 7% Full Year Organic Revenue Growth – – Acquisition by GI Partners for $12.25 per share remains on track to close in Second Quarter 2023 – AUSTIN, Texas, March 16, 2023 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading infrastructure and environmental services provider, announced today results for the fourth quarter and full year ended December 30, 2022. Fourth Quarter 2022 Highlights:(all comparisons versus the prior-year period unless otherwise noted)Gross revenue grew 4% to $151.0 million. Gross margin, excluding subcontractor costs, was 61.4%, up 400 basis points; operating margin, excluding subcontractor costs, was 7.5%, up 320 basis points. Net loss was $4.2 million. Adjusted net income...